media – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

21 Health News Daily | The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes; The National Medical Products Administration approves the launch of China’s first stem cell therapy drug

The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes On January 2nd, the National Healthcare Security Administration issued a document clarifying the comprehensive promotion of “code based” strict supervision from January 1st, 2025. It will fully leverage the value of drug traceability code data, build various big data models, expand regulatory application scenarios, and carry out precise crackdowns on illegal and irregular use of medical insurance funds such as swapping and reselling medical insurance drugs, empty brushing and brushing medical insurance cards, and forging prescriptions, and increase the intensity of disposal. The drug traceability code is the only “electronic ID card” for drugs. In April 2024, the National Healthcare Security Administration launched a pilot project for the collection and application of drug traceability codes nationwide. In early November 2024, a public inquiry was conducted on 46 designated pharmaceutical institutions regarding the repeated reimbursement of a ...
- Source: drugdu
- 122
- January 4, 2025
Deeply focusing on the chronicity of tumors, Sinopharm is about to enter the harvest period of the global market

More convenient drug delivery methods, lower side effects, and higher survival rates… In the already booming field of anti-tumor drugs, there are still competitors constantly providing better solutions. Recently, the FDA approved the marketing of BMS’s Opdivo subcutaneous injection Opdivo Qvantig (nivolumab plus hyaluronidase), which also means that Opdivo is a latecomer, crossing the “KO battle” and becoming an earlier PD-1 subcutaneous formulation approved for marketing. Compared with the traditional intravenous infusion method that usually lasts for more than half an hour, subcutaneous preparations can be administered within 3-5 minutes, greatly improving patient comfort and convenience in medication. Of course, this administration method also has certain requirements for the difficulty of drug development. In September 2024, Roche also released a subcutaneous version of its PD-L1 antibody Tecentriq. It is worth noting that the subcutaneous formulation version of PD-L1 drugs does not come from multinational pharmaceutical companies, but from domestic innovative ...
- Source: drugdu
- 95
- January 4, 2025
SAP’s massive layoffs

According to foreign media reports, the world’s third-largest software company is undergoing large-scale layoffs. German software giant SAP, the world’s third-largest software company, is cutting 9000 to 10000 positions instead of the original 8000 positions. Among them, in Germany, plans are underway to lay off approximately 3500 out of 25000 employees through early retirement and layoffs, accounting for 14%. Insiders revealed that initially around 5300 people expressed interest in the plan. However, SAP rejected many applications to prevent the loss of critical technologies. Among the nearly 3500 approved volunteer employees, about 80% retired early, about 2800 people, and 20% received severance pay plans. Public information shows that SAP was founded in 1972 and was once ranked as the world’s third largest software company by Forbes magazine. The company is dedicated to SAP, an enterprise management software business, and its potential market competitor is the American company Oracle. In the field ...
- Source: drugdu
- 30
- January 4, 2025
Innovent Biologics and Roche have reached a global exclusive licensing agreement for the new generation of DLL3 antibody conjugated drugs

On January 2, 2025, San Francisco, USA and Suzhou, China – Xinda Biopharmaceutical Group (hereinafter referred to as “Xinda Biopharmaceutical”), a biopharmaceutical company dedicated to the research and development, production, and sales of innovative drugs in major disease fields such as oncology, autoimmune, cardiovascular and metabolic, and ophthalmology, announced today that it has reached a global exclusive cooperation and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to promote the development of IBI3009, a new generation of antibody coupled drug (ADC) candidate products targeting Delta like ligand 3 (DLL3), aiming to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). IBI3009 has currently obtained clinical application (IND) approval in Australia, China, and the United States, and the first patient in phase I clinical trials will be administered in December 2024. IBI3009： Potential best in class DLL3 ADC candidate drugs IBI3009 specifically targets DLL3, an ...
- Source: drugdu
- 123
- January 4, 2025
The bill “failed”, WuXi Biologics is back

WuXi Biologics is back. Since the progress of the US Biosafety Act has continued to jump sideways, WuXi Biologics’ stock price performance has been suppressed before September. As the company’s stock price rose to more than 3% today and closed up 2.19%, it not only outperformed the Hang Seng Index and Hang Seng Medical ETF, but the company’s overall recent trend has continued to improve (a cumulative increase of 58.21% since September 2024). This is due to the fact that the negative shoe finally landed. According to the latest news from the US House of Representatives bill, the Biosafety Act was not included in the 2025 NDAA (National Defense Security Act), which objectively confirmed the failure of the bill’s rapid legislation. In addition, according to recent news, the 2025 Continuing Appropriations and Extension Act (CR Act) announced by the US Congress also did not include the Biosafety Act. WuXi Biologics ...
- Source: drugdu
- 80
- January 4, 2025
A major breakthrough in solid tumor CAR-T, the key clinical success of domestic CAR-T therapy in the treatment of gastric cancer

On the morning of December 30, Keji Pharmaceutical (02171.HK) announced that China’s pivotal Phase II clinical trial of Serigene Oronza Injection for the treatment of advanced gastric/esophagogastric junction adenocarcinoma has obtained preliminary positive results. ▍About Sulgid Oronza Injection According to the announcement, this trial is a randomized controlled, multi-center clinical trial conducted in China, aiming to evaluate the treatment of Shuruiji Olense Injection (CT041) in the treatment of advanced patients with positive Claudin18.2 expression who have failed at least 2 lines of treatment in the past. Efficacy and safety in gastric/esophagogastric junction adenocarcinoma. The trial achieved its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC). There was a statistically significant improvement in progression-free survival among subjects in the Serigen-Olenza injection group compared with the investigator’s choice treatment group. Previous test data shows that the safety of this product is controllable. Shuregen Orenza Injection is ...
- Source: drugdu
- 113
- January 4, 2025
The chairman of the board of directors of the “first cancer early screening stock” was removed

Today, Nova Health, a leading company in the field of early cancer screening, has experienced major personnel changes. On December 31 (today), Nova Health announced that Mr. Zhu Yeqing has resigned as Chairman of the Board (“Chairman”) and Chief Executive Officer of the Company (“CEO”) on December 30, 2024 due to personal health reasons, effective from the same date (“Resignation”). At the same time, the announcement pointed out that the board of directors believes that Mr. Zhu Yeqing’s management style and philosophy are significantly different from those of other members of the board of directors, and allowing Mr. Zhu Yeqing to continue to participate in the management of the company is not in the overall best interests of the company and its shareholders. Given that Mr. Zhu Yeqing only resigned from the positions of Chairman and Chief Executive Officer, not the position of Executive Director, the board of directors has ...
- Source: drugdu
- 41
- January 4, 2025
“The world’s first” subcutaneous PD-1 is approved for marketing, covering 12 tumor types

On December 27, local time, the US FDA announced that it had approved Bristol-Myers Squibb’s “Nivolumab” subcutaneous injection (Opdivo Qvantig) for marketing, for the treatment of adult solid tumor indications previously approved for its intravenous injection Opdivo. This is the world’s first approved subcutaneous PD-1 inhibitor. ▍Approved indications The approved indications for subcutaneous injection of Nivolumab include renal cell carcinoma, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Screenshot source: FDA official website Nivolumab is the world’s first approved PD-1 inhibitor. It has been approved for marketing in more than 65 countries and regions including the United States, the European Union, Japan and China, covering 12 tumor types, including lung cancer, head and neck cancer, gastric cancer, esophageal cancer, liver cancer, kidney cancer, colorectal cancer, urothelial carcinoma, melanoma, Hodgkin’s lymphoma, pleural ...
- Source: drugdu
- 87
- January 4, 2025
The market size of health products exceeds 300 billion, with silver haired and post-90s generations as the main consumers

According to the Statistical Bulletin on the Development of Civil Affairs in 2023, as of the end of 2023, the population of elderly people aged 60 and above in China will be close to 300 million, accounting for 21.1% of the total population. According to international standards, Chinese society has entered a stage of moderate aging. The deepening of aging population and the improvement of health awareness have become important factors in the rise of the health product market. Especially with the sinking and popularization of e-commerce channels, purchasing health products has become more convenient. While nurturing opportunities, the industry also harbors many consumer traps. Starting from multiple dimensions such as overall market size, category track, channel distribution, and consumer attributes, the New Beijing News reporter presents the current development status of the domestic health product industry from different perspectives, insights into consumer trends, and faces the opportunities and crises ...
- Source: drugdu
- 193
- January 3, 2025
priced higher than semaglutide, it is a self funded medication

Novo Nordisk’s strongest competitor, semaglutide, has officially been commercialized and launched in China. On December 25th, a reporter from The Paper noticed that several e-commerce platforms now offer diagnosis, treatment, and medication services for Eli Lilly’s glucose dependent insulinotropic polypeptide (GIP)/glucagon like peptide-1 (GLP-1) receptor agonist tilboptin (trade name: Mufengda). The indications of tilporide include diabetes and weight loss. At present, the prices of various businesses on the platform are different, and it is suggested that the specific price should be subject to the final selected store price. image Multiple e-commerce platforms offer the option to purchase Eli Lilly and its derivatives Taking an Internet hospital business as an example, the quotation of 0.5ml: 2.5mg * 4 pieces is 2480 yuan, and the single piece price is 620 yuan. The merchant claims that their drugs are authentic, quickly registered, and reserved for appointment. The reporter from Pengpai News contacted the ...
- Source: drugdu
- 189
- January 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.